Literature DB >> 2834209

Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function.

B A van Schaik1, G G Geyskes, P A van der Wouw, H H van Rooij, A J Porsius.   

Abstract

The pharmacokinetics of lisinopril was studied after administration of single and multiple doses of 5 mg to hypertensive patients with normal and impaired renal function. In patients with severe renal failure the peak concentrations were higher, the decline in serum concentration was slower and the time to peak concentration was extended. Accumulation of lisinopril was highly correlated with the creatinine clearance. The effective half-life was doubled and tripled in patients with mild and severe renal impairment, respectively, as compared to patients with a normal renal function. Lisinopril lowered blood pressure in all three groups over 24 h. It is suggested that smaller doses of lisinopril should be administered to patients with severe renal failure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834209     DOI: 10.1007/BF01061419

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.

Authors:  P Mojaverian; M L Rocci; P H Vlasses; C Hoholick; R A Clementi; R K Ferguson
Journal:  J Pharm Sci       Date:  1986-04       Impact factor: 3.534

2.  Drug dosage in patients with renal disease.

Authors:  L C Dettli
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

3.  Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.

Authors:  D B Brunner; G Desponds; J Biollaz; I Keller; F Ferber; H Gavras; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

4.  Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitor.

Authors:  H H Rotmensch; P H Vlasses; B N Swanson; J D Irvin; K E Harris; D G Merrill; R K Ferguson
Journal:  Am J Cardiol       Date:  1984-01-01       Impact factor: 2.778

5.  Lisinopril in hypertensive patients with and without renal failure.

Authors:  B A van Schaik; G G Geyskes; P Boer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

Authors:  G P Hodsman; J R Zabludowski; C Zoccali; R Fraser; J J Morton; G D Murray; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

7.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

Authors:  J A Millar; F H Derkx; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

8.  Enalapril maleate and a lysine analogue (MK-521): disposition in man.

Authors:  E H Ulm; M Hichens; H J Gomez; A E Till; E Hand; T C Vassil; J Biollaz; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

9.  Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.

Authors:  J Biollaz; J L Schelling; B Jacot Des Combes; D B Brunner; G Desponds; H R Brunner; E H Ulm; M Hichens; H J Gomez
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

  9 in total
  10 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 3.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

4.  Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.

Authors:  R Greenbaum; P Zucchelli; A Caspi; H Nouriel; R Paz; S Sclarovsky; P O'Grady; K F Yee; W C Liao; B Mangold
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Authors:  J Hoyer; K L Schulte; T Lenz
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

6.  Pharmacokinetics and pharmacodynamics of lisinopril in advanced renal failure. Consequence of dose adjustment.

Authors:  M Neubeck; D Fliser; M Pritsch; K Weisser; M Fliser; J Nussberger; E Ritz; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.

Authors:  D A Sica; R E Cutler; R J Parmer; N F Ford
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

9.  Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection.

Authors:  H Trachtman; A Frymoyer; A Lewandowski; L A Greenbaum; D I Feig; D S Gipson; B A Warady; J W Goebel; G J Schwartz; K Lewis; R Anand; U D Patel
Journal:  Clin Pharmacol Ther       Date:  2015-05-02       Impact factor: 6.903

10.  Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model.

Authors:  Memoona Rashid; Muhammad Sarfraz; Mosab Arafat; Amjad Hussain; Nasir Abbas; Muhammad Waqas Sadiq; Muhammad Fawad Rasool; Nadeem Irfan Bukhari
Journal:  BMC Pharmacol Toxicol       Date:  2020-07-29       Impact factor: 2.483

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.